Alpha-Synucleinopathy-Associated Neurons

Alpha-Synucleinopathy-Associated Neurons

<table class="infobox infobox-cell">
<tr>
<th class="infobox-header" colspan="2">Alpha-Synucleinopathy-Associated Neurons</th>
</tr>
<tr>
<td class="label">Taxonomy</td>
<td>ID</td>
</tr>
<tr>
<td class="label">Cell Ontology (CL)</td>
<td>[CL:0000095](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000095)</td>
</tr>
<tr>
<td class="label">Database</td>
<td>ID</td>
</tr>
<tr>
<td class="label">Cell Ontology</td>
<td>[CL:0000095](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000095)</td>
</tr>
<tr>
<td class="label">Cell Ontology</td>
<td>[CL:0004117](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0004117)</td>
</tr>
<tr>
<td class="label">Stage</td>
<td>Species</td>
</tr>
<tr>
<td class="label">1</td>
<td>Monomeric α-Syn</td>
</tr>
<tr>
<td class="label">2</td>
<td>Oligomeric α-Syn</td>
</tr>
<tr>
<td class="label">3</td>
<td>Protofibrils</td>
</tr>
<tr>
<td class="label">4</td>
<td>Fibrils</td>
</tr>
<tr>
<td class="label">Gene</td>
<td>Effect on α-Syn Pathology</td>
</tr>
<tr>
<td class="label">SNCA multiplication</td>
<td>Increased expression, earlier onset</td>
</tr>
<tr>
<td class="label">GBA1 mutations</td>
<td>Higher burden, faster progression</td>
</tr>
<tr>
<td class="label">LRRK2 mutations

...

Alpha-Synucleinopathy-Associated Neurons

<table class="infobox infobox-cell">
<tr>
<th class="infobox-header" colspan="2">Alpha-Synucleinopathy-Associated Neurons</th>
</tr>
<tr>
<td class="label">Taxonomy</td>
<td>ID</td>
</tr>
<tr>
<td class="label">Cell Ontology (CL)</td>
<td>[CL:0000095](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000095)</td>
</tr>
<tr>
<td class="label">Database</td>
<td>ID</td>
</tr>
<tr>
<td class="label">Cell Ontology</td>
<td>[CL:0000095](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000095)</td>
</tr>
<tr>
<td class="label">Cell Ontology</td>
<td>[CL:0004117](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0004117)</td>
</tr>
<tr>
<td class="label">Stage</td>
<td>Species</td>
</tr>
<tr>
<td class="label">1</td>
<td>Monomeric α-Syn</td>
</tr>
<tr>
<td class="label">2</td>
<td>Oligomeric α-Syn</td>
</tr>
<tr>
<td class="label">3</td>
<td>Protofibrils</td>
</tr>
<tr>
<td class="label">4</td>
<td>Fibrils</td>
</tr>
<tr>
<td class="label">Gene</td>
<td>Effect on α-Syn Pathology</td>
</tr>
<tr>
<td class="label">SNCA multiplication</td>
<td>Increased expression, earlier onset</td>
</tr>
<tr>
<td class="label">GBA1 mutations</td>
<td>Higher burden, faster progression</td>
</tr>
<tr>
<td class="label">LRRK2 mutations</td>
<td>Variable effects</td>
</tr>
<tr>
<td class="label">PARK2/PARKIN</td>
<td>Less Lewy bodies (paradox)</td>
</tr>
<tr>
<td class="label">Strategy</td>
<td>Example</td>
</tr>
<tr>
<td class="label">Aggregation inhibitors</td>
<td>Anle138b</td>
</tr>
<tr>
<td class="label">Immunotherapy</td>
<td>Prasinezumab</td>
</tr>
<tr>
<td class="label">Gene therapy</td>
<td>AAV-AADC</td>
</tr>
<tr>
<td class="label">Cell replacement</td>
<td>iPSC-dopamine</td>
</tr>
<tr>
<td class="label">Stage</td>
<td>Affected Regions</td>
</tr>
<tr>
<td class="label">1</td>
<td>DMV, LC</td>
</tr>
<tr>
<td class="label">2</td>
<td>Lower brainstem</td>
</tr>
<tr>
<td class="label">3</td>
<td>SNc, amygdala</td>
</tr>
<tr>
<td class="label">4</td>
<td>Temporal cortex</td>
</tr>
<tr>
<td class="label">5-6</td>
<td>Neocortex</td>
</tr>
</table>

Overview

Alpha Synucleinopathy Associated Neurons plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.

<!-- taxonomy-enrichment -->

<!-- multi-taxonomy-enrichment -->

Multi-Taxonomy Classification

Taxonomy Database Cross-References

Morphology & Electrophysiology

• Morphology: neuron associated cell (source: Cell Ontology)
• Morphology can be inferred from Cell Ontology classification

PanglaoDB Marker Cross-References

• Unknown (PanglaoDB):

External Database Links

• [Cell Ontology (CL:0000095)](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000095)
• [OBO Foundry (CL:0000095)](http://purl.obolibrary.org/obo/CL_0000095)
• [Allen Brain Cell Atlas](https://portal.brain-map.org/atlases-and-data/bkp/abc-atlas)
• [CellxGene Census](https://cellxgene.cziscience.com/)
• [Human Cell Atlas](https://www.humancellatlas.org/)
• [PanglaoDB](https://panglaodb.se/)

Taxonomy & Classification

PanglaoDB Marker Cross-References

• Unknown (PanglaoDB):

External Database Links

• [Cell Ontology (CL:0000095)](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000095)
• [OBO Foundry (CL:0000095)](http://purl.obolibrary.org/obo/CL_0000095)
• [Allen Brain Cell Atlas](https://portal.brain-map.org/atlases-and-data/bkp/abc-atlas)
• [CellxGene Census](https://cellxgene.cziscience.com/)
• [PanglaoDB](https://panglaodb.se/)

Introduction

Alpha-synucleinopathy-associated neurons are neurons that accumulate pathological alpha-synuclein (α-Syn) aggregates in the form of Lewy bodies and Lewy neurites. These proteinaceous inclusions characterize a group of neurodegenerative diseases collectively termed synucleinopathies, including Parkinson's disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA)[@spillantini1997][@braak2003]. Understanding which neuronal populations are vulnerable to alpha-synuclein pathology, and why, is critical for developing disease-modifying therapies.

Vulnerable Neuronal Populations

Substantia Nigra Pars Compacta

The most prominently affected region in PD[@kalia2015]:

• Dopaminergic neurons: 50-70% loss by clinical diagnosis
• Neuromelanin-containing neurons: Selective vulnerability
• A9 neurons: Most affected
• A10 neurons: Relatively spared

Why SNc Neurons Are Vulnerable

High oxidative metabolism: Dopamine auto-oxidation

Neuromelanin accumulation: Iron chelation and pro-oxidant

Pacemaker activity: Calcium influx

Long axons: Transport burden

Mitochondrial stress: Complex I deficiency

Limbic System

Early involvement in disease progression:

• Hippocampal CA2/3 neurons: Memory circuit disruption
• Amygdala neurons: Emotional processing deficits
• Entorhinal cortex: Grid cell dysfunction
• Subiculum: Output pathway

Lower Brainstem

Pathological staging reveals early involvement:

• Dorsal motor nucleus of vagus (DMN): Stage 1 involvement
• Locus coeruleus: Noradrenergic neurons
• Raphe nuclei: Serotonergic neurons
• Pedunculopontine nucleus: Gait dysfunction

Peripheral Nervous System

• Enteric nervous system: GI tract involvement
• Vagus nerve: Prion-like spread hypothesis
• Sympathetic ganglia: Cardiac denervation
• Salivary glands: Early biomarker source

Cortical Regions

• Frontal cortex: Executive dysfunction
• Temporal cortex: Language deficits
• Parietal cortex: Visuospatial impairment
• Primary sensory areas: Sensory processing

Molecular Pathology

Alpha-Synuclein Aggregation Cascade

The pathological process involves protein misfolding and aggregation[@lashuel2013]:

Lewy Body Composition

• Phosphorylated α-Syn (Ser129): Major component
• Ubiquitinated proteins: Degradation attempts
• Neurofilaments: Scaffold proteins
• Molecular chaperones: Hsp70, Hsp90

Strain Diversity

Different α-Syn strains:

• PD-type: Cortical, diffuse
• MSA-type: Glial cytoplasmic inclusions
• DLB-type: Limbic, cortical

Genetic Modifiers

Risk Factors

Protective Factors

• SNCA promoter variants: Reduced expression
• LRRK2 G2019S: May reduce pathology (controversial)

Cell Death Mechanisms

Primary Pathways

Mitochondrial dysfunction:

• Complex I inhibition
• ATP depletion
• ROS generation

ER stress:

• Unfolded protein response
• CHOP activation
• Apoptosis

Oxidative stress:

• Dopamine oxidation
• Lipid peroxidation
• DNA damage

Membrane pore formation:

• Oligomeric α-Syn pores
• Calcium dysregulation
• Homeostasis failure

Transport disruption:

• Axonal transport defects
• Mitochondrial trafficking
• Synaptic dysfunction

Neuronal Vulnerability Factors

Intrinsic Factors

• Metabolic demand: High energy requirements
• Calcium handling: Pacemaker activity
• Protein clearance: Age-related decline
• Axonal length: Transport burden
• Neuromelanin: Iron accumulation

Extrinsic Factors

• Microglial activation: Neuroinflammation
• Vascular supply: Perfusion deficits
• Network activity: Functional demands

Therapeutic Implications

Disease-Modifying Strategies

Neuroprotective Approaches

• Antioxidants: CoQ10, vitamin E, edaravone
• Calcium channel blockers: L-type blockers
• GLP-1 agonists: Exenatide (clinical trials)
• Mitochondrial protectants: MitoQ

Symptomatic Treatments

• Dopamine replacement: L-DOPA, agonists
• Monoamine oxidase B inhibitors: Selegiline, rasagiline
• COMT inhibitors: Entacapone

Braak Staging

The progression of α-Syn pathology follows a characteristic pattern[@del2016]:

Research Methods

Biomarker Development

• CSF α-Syn: Phospho-Ser129
• Skin biopsies: Autonomic nerves
• Olfactory testing: Early detection
• PET ligands: In vivo imaging

Model Systems

• Transgenic mice: A53T, A30P
• Viral vectors: AAV-SNCA
• iPSC neurons: Patient-derived
• Organoids: 3D models

Key Publications

[Spillantini MG, et al. Alpha-synuclein in Lewy bodies. Nature. 1997](https://doi.org/10.1038/42166)

[Braak H, et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging. 2003](https://doi.org/10.1016/s0197-4580(02)00065-9)

[Kalia LV, Lang AE. Parkinson's disease. Lancet. 2015](https://doi.org/10.1016/S0140-6736(14)61393-3)

[Lashuel HA, et al. The many faces of alpha-synuclein. J Mol Biol. 2013](https://doi.org/10.1016/j.jmb.2013.04.007)

[Peelaerts W, et al. Alpha-Synuclein strains. Nature. 2015](https://doi.org/10.1038/nature14547)

• Parkinson Disease
• [Dementia with Lewy Bodies](/diseases/lewy-body-dementia)
• [Multiple System Atrophy](/diseases/multiple-system-atrophy)
• [Alpha-Synuclein](/proteins/alpha-synuclein) SNCA Gene
• Substantia Nigra
• Lewy Bodies

Overview

Alpha Synucleinopathy Associated Neurons plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.

Background

The study of Alpha Synucleinopathy Associated Neurons has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

External Links

• [Lewy Body Dementia Association](https://www.lbda.org/)
• [Michael J. Fox Foundation](https://www.michaeljfox.org/)
• [Parkinson's Foundation](https://www.parkinson.org/)
• [Alpha-Synuclein Research - NIH](https://www.ninds.nih.gov/)

Pathway Diagram

The following diagram shows the key molecular relationships involving Alpha-Synucleinopathy-Associated Neurons discovered through SciDEX knowledge graph analysis: